LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
Can you take Wegovy with Jardiance? Yes, these two medications can generally be used together under specialist supervision, though careful monitoring is essential. Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist licensed for weight management in adults with obesity or overweight with comorbidities, whilst Jardiance (empagliflozin) is an SGLT2 inhibitor licensed for type 2 diabetes, heart failure, and chronic kidney disease. There is no official contraindication to their concurrent use, and they work through different mechanisms that may offer complementary metabolic benefits. However, combination therapy requires individualised assessment by your GP or diabetes specialist, including evaluation of kidney function, cardiovascular status, and other medications, with ongoing monitoring to ensure safe and effective treatment.
Quick Answer: Wegovy and Jardiance can generally be taken together under specialist supervision, as there is no official contraindication to their concurrent use when appropriately prescribed.
Yes, Wegovy (semaglutide 2.4mg) and Jardiance (empagliflozin) can generally be taken together under specialist supervision, though each medication is licensed for different purposes in the UK. There is no official contraindication to their concurrent use when appropriately prescribed.
Wegovy is specifically licensed for weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. In the NHS, Wegovy is typically only available through specialist weight management services and may have stricter BMI thresholds for eligibility (note that lower BMI thresholds may apply for people from certain ethnic backgrounds). It's important to distinguish Wegovy from Ozempic, which is the same molecule (semaglutide) but at lower doses and licensed for type 2 diabetes treatment.
Jardiance belongs to the sodium-glucose co-transporter 2 (SGLT2) inhibitor class and is licensed for type 2 diabetes management, heart failure, and chronic kidney disease. When used together, these medications address different pathophysiological mechanisms, potentially offering complementary benefits for patients with multiple metabolic conditions.
However, combination therapy requires careful clinical oversight. Your GP or diabetes specialist will assess your individual circumstances, including your current metabolic control, kidney function, cardiovascular status, and other medications. The decision to prescribe both drugs simultaneously should be based on a thorough evaluation of potential benefits against any risks specific to your health profile. Never start, stop, or combine these medications without explicit guidance from your healthcare team, as dosing adjustments and enhanced monitoring may be necessary to ensure safe and effective treatment.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
Understanding the distinct mechanisms of action of Wegovy and Jardiance helps explain why they can be used together and how they complement each other in managing metabolic conditions.
Wegovy (semaglutide) is a long-acting GLP-1 receptor agonist that mimics the action of naturally occurring incretin hormones. It works through several mechanisms:
Appetite regulation: Semaglutide acts on receptors in the brain's appetite centres, particularly the hypothalamus, reducing hunger and increasing satiety after meals
Delayed gastric emptying: It slows the rate at which food leaves the stomach, prolonging feelings of fullness (this effect may be most pronounced during dose escalation)
Glucose-dependent insulin secretion: In the presence of elevated blood glucose, it stimulates pancreatic beta cells to release insulin
Glucagon suppression: It reduces inappropriate glucagon secretion from pancreatic alpha cells, thereby limiting hepatic glucose production
These combined effects result in significant weight loss—around 15% of body weight in people without diabetes and approximately 9-10% in people with type 2 diabetes, according to clinical trials—and improved glycaemic control in people with type 2 diabetes.
Jardiance (empagliflozin) operates through an entirely different mechanism as an SGLT2 inhibitor:
Renal glucose excretion: It blocks SGLT2 transporters in the proximal renal tubules, preventing glucose reabsorption and promoting urinary glucose elimination (typically 60–90g daily)
Osmotic diuresis: The glucose excretion is accompanied by modest fluid loss, contributing to blood pressure reduction
Metabolic effects: The urinary glucose excretion results in caloric loss and may contribute to changes in energy metabolism
Cardiovascular and renal protection: Beyond glucose lowering, SGLT2 inhibitors demonstrate cardioprotective and nephroprotective effects through mechanisms that are still being fully elucidated
Because these medications work through independent pathways—one primarily affecting appetite and insulin secretion, the other promoting glucose elimination—they can be combined without mechanistic interference, potentially offering complementary metabolic benefits.
There is no direct pharmacokinetic interaction between Wegovy and Jardiance, meaning neither medication significantly affects how the other is absorbed, distributed, metabolised, or eliminated from the body. This pharmacological independence is reassuring and supports their safe co-administration in appropriate patients.
However, pharmacodynamic considerations—how the drugs' effects combine in the body—warrant attention:
Additive glucose-lowering effects: Both medications reduce blood glucose levels through different mechanisms. When used together, particularly in patients also taking other antidiabetic medications (such as insulin or sulphonylureas), there is a theoretical increased risk of hypoglycaemia. GLP-1 receptor agonists like Wegovy have glucose-dependent insulin secretion (reducing hypoglycaemia risk), while SGLT2 inhibitors like Jardiance have low hypoglycaemia risk because they do not directly stimulate insulin. However, the risk increases when either is combined with insulin or sulphonylureas.
Gastrointestinal effects: Wegovy commonly causes nausea, vomiting, and diarrhoea, especially during dose escalation. Jardiance's primary side effects include genital mycotic infections, urinary tract infections, polyuria, and thirst, though it can occasionally contribute to volume depletion. If significant gastrointestinal side effects occur with Wegovy, the fluid loss could be compounded by Jardiance's diuretic effect, potentially increasing dehydration risk.
Weight loss considerations: Both medications promote weight loss—Wegovy through appetite suppression and Jardiance through caloric loss via urinary glucose excretion (approximately 200–300 calories daily). The combined weight loss effect is generally beneficial for patients with obesity and type 2 diabetes, but monitoring is essential to ensure weight loss remains within healthy parameters.
Renal function: For its diabetes indication, Jardiance is not recommended when eGFR falls below 45 mL/min/1.73m², though it may be used at lower eGFR thresholds (typically ≥20 mL/min/1.73m²) for heart failure or chronic kidney disease indications per the current SmPC. It is contraindicated in patients on dialysis. Wegovy does not require dose adjustment in renal impairment, but caution is needed due to increased risk of dehydration and acute kidney injury if significant gastrointestinal side effects occur. Your healthcare team will monitor kidney function regularly when these medications are used together.
When taking Wegovy and Jardiance concurrently, several important safety considerations require attention and ongoing monitoring:
Dehydration and volume depletion: This represents one of the most significant concerns with combination therapy. Jardiance promotes fluid loss through its diuretic effect, whilst Wegovy may cause nausea, vomiting, or diarrhoea, particularly during the initial weeks of treatment or dose escalation. To minimise risk:
Maintain adequate hydration as advised by your clinician (some people, such as those with heart failure or kidney disease, may need fluid restriction rather than increased intake)
Be vigilant during hot weather, exercise, or illness
Watch for signs of dehydration: dizziness, dry mouth, reduced urine output, dark urine, or postural lightheadedness
Contact your GP promptly if you experience persistent vomiting or diarrhoea
Diabetic ketoacidosis (DKA): SGLT2 inhibitors like Jardiance carry a small risk of euglycaemic DKA—a serious condition where ketones accumulate even when blood glucose levels are not markedly elevated. Important safety measures include:
Temporarily stopping Jardiance during acute illness, dehydration, or if unable to eat and drink normally
Pausing Jardiance for at least 3 days before planned surgery or procedures
Testing blood or urine ketones if you feel unwell, even if blood glucose is not high
Seeking immediate medical attention if you develop symptoms of DKA:
Genital and urinary tract infections: Jardiance increases glucose in the urine, which can promote fungal and bacterial infections, particularly genital thrush and urinary tract infections. Maintain good hygiene and report symptoms such as itching, discharge, burning on urination, or increased urinary frequency to your healthcare provider.
Fournier's gangrene: This is a rare but serious infection of the genitals and perineum associated with SGLT2 inhibitors. Seek urgent medical attention if you experience severe pain, tenderness, redness, or swelling in the genital or perineal area, especially if accompanied by fever or malaise.
Pancreatitis and gallbladder disease: GLP-1 receptor agonists like Wegovy have been associated with acute pancreatitis and gallbladder problems in rare cases. Discontinue Wegovy and seek urgent medical assessment if you develop severe, persistent abdominal pain, particularly if radiating to the back and accompanied by vomiting.
Diabetic retinopathy: If you have pre-existing diabetic retinopathy and diabetes, rapid improvement in glucose control with semaglutide may temporarily worsen eye problems. Report any visual changes promptly to your healthcare provider.
Pregnancy and breastfeeding: Wegovy is contraindicated during pregnancy and should be avoided during breastfeeding. Effective contraception is recommended for women of childbearing potential using Wegovy.
Medication adjustments: If you take other diabetes medications, particularly insulin or sulphonylureas (such as gliclazide), your doses may require reduction when starting either Wegovy or Jardiance to prevent hypoglycaemia. Never adjust doses independently—always follow your healthcare team's guidance.
Regular monitoring should include blood glucose levels (if you have diabetes), kidney function tests, blood pressure, and weight tracking to assess treatment response and identify any emerging concerns early.
If you experience any suspected side effects, report them to the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.
Before starting or continuing combination therapy with Wegovy and Jardiance, have a comprehensive discussion with your healthcare team covering the following important areas:
Your complete medical history, including:
Current and previous diabetes control (HbA1c levels)
Kidney function and any history of renal disease
Cardiovascular conditions, including heart failure or previous heart attacks
History of pancreatitis or gallbladder disease
Previous episodes of diabetic ketoacidosis
Diabetic retinopathy status and recent eye examinations
Recurrent urinary or genital infections
Any planned surgical procedures
Pregnancy plans or current breastfeeding (Wegovy is contraindicated in pregnancy)
Your current medication regimen: Provide a complete list of all medications, including:
Other diabetes medications (insulin, sulphonylureas, metformin, etc.)
Blood pressure medications, particularly diuretics
Over-the-counter medications and supplements
Any medications that affect kidney function
Your healthcare team will assess potential interactions and may need to adjust doses or timing of other medications.
NHS access criteria for Wegovy: Discuss whether you meet the criteria for NHS-funded treatment, which typically includes:
Treatment within a specialist weight management service
Meeting specific BMI thresholds (potentially higher than the licensed thresholds)
Understanding treatment duration limitations
Treatment goals and expectations: Clarify what you hope to achieve with combination therapy, whether primarily weight loss, improved glycaemic control, cardiovascular protection, or a combination of benefits. Discuss realistic timelines and expected outcomes based on clinical evidence.
Monitoring plan: Establish a clear schedule for:
Blood glucose monitoring (frequency and target ranges)
HbA1c testing (typically every 3–6 months)
Kidney function tests (eGFR and urine albumin-to-creatinine ratio)
Blood pressure checks
Weight monitoring
Follow-up appointments
Practical considerations:
Injection technique for Wegovy (administered once weekly subcutaneously)
Timing of Jardiance (usually once daily in the morning)
Managing side effects, particularly gastrointestinal symptoms from Wegovy
Sick day rules—specifically when to temporarily stop Jardiance (during acute illness, dehydration, or 3 days before surgery)
When and how to monitor ketones if unwell
Contraception planning if applicable
Cost implications and prescription arrangements
When to seek urgent medical attention: Ensure you understand warning signs requiring immediate healthcare contact, including symptoms of DKA, severe dehydration, Fournier's gangrene, pancreatitis, or unexplained illness.
Your healthcare team should provide you with written information and emergency contact details. NICE guidance supports individualised treatment approaches for type 2 diabetes and obesity, emphasising shared decision-making between patients and clinicians. Regular review appointments allow for treatment optimisation and early identification of any concerns, ensuring you receive maximum benefit from combination therapy whilst minimising risks.
There is no direct pharmacokinetic interaction between Wegovy and Jardiance, meaning neither medication significantly affects how the other is absorbed or eliminated. However, pharmacodynamic considerations exist, including additive glucose-lowering effects and potential for increased dehydration risk, requiring careful clinical monitoring.
The primary safety concerns include dehydration and volume depletion (as Jardiance promotes fluid loss and Wegovy may cause gastrointestinal side effects), risk of diabetic ketoacidosis with Jardiance, increased genital and urinary tract infections, and potential hypoglycaemia if combined with insulin or sulphonylureas. Regular monitoring of kidney function, blood glucose, and hydration status is essential.
Combination therapy with Wegovy and Jardiance should be prescribed and monitored by your GP or diabetes specialist. Wegovy is typically only available through specialist weight management services in the NHS, and the decision to use both medications requires thorough assessment of your individual circumstances, including metabolic control, kidney function, cardiovascular status, and other medications.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
